Articles

Key View: We hold a positive outlook for Croatia's consumer activity over 2024, with support for spending and confidence coming from a strengthening economic backdrop, easing inflation and jobs and earnings growth. Consumer confidence has been improving steadily over the last few months of 2023 and with inflation easing over the same period, this

We retain our mixed short-term outlook for the currencies that we cover in the Middle East and North Africa (MENA) region. All of the MENA currencies we track closely have weakened so far this year, albeit to different degrees (see chart below). 

In Israel, the ongoing war in Gaza and rising tensions with Iran led to a nearly 5.0% depreciation

Key View:

• The economic feasibility of importing hydrogen as opposed to developing domestic hydrogen production hinges on comprehensive cost analyses across various markets. Transporting hydrogen by sea becomes cost-effective for distances exceeding 2,500 kilometers, necessitating advanced infrastructure and strategic decisions regarding

Please Note: BMI is enhancing its risk analysis with a new scoring system following its acquisition of GeoQuant, a market-leading provider of political risk data. From March 27 2024, risk scores are inverted: zero now represents the lowest risk and 100 represents the highest risk. This allows for clearer, industry-standard assessments. For

Latest Development: Smart Communications (Smart), a subsidiary of incumbent, Philippines-based operator PLDT, has initiated a campaign to boost eSIM adoption among prepaid customers, offering current Smart subscribers an upgrade to eSIM for PHP99 (USD1.75) while retaining their number, and providing non-Smart users the option to switch to Smart

Key View

• The limited nature of Israel’s retaliation against Iran on April 18/19, and Iran’s muted response, suggest that both sides are seeking to de-escalate tensions, which is now the likeliest scenario.
• Indeed, the reaction in oil markets was muted, and oil price futures are already declining. If Israel and Iran remain on this de

Latest Development: In a significant shift in regulatory approach, the FDA is urging Congress to eliminate the interchangeability designation that has long differentiated biosimilars in the US market. This proposed legislative change is set to resolve the confusion stemming from a two-tier system that has inadvertently created misconceptions about

Key View 

• Alvotech will be the global frontrunner for ustekinumab biosimilars following its latest approval of Selarsdi in the US.  
• Johnson & Johnson will delay new entrants with ongoing patent litigation settlements, although the 2024 and 2025 patent cliffs are quickly approaching.  
• Stelara revenue will be impacted immediately following